This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.
Product Usage:
This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.
CAGRILINTIDE + SEMAGLUTIDE
$
189 AUD
Product Info
Cagrilintide + Semaglutide is a combination of two synthetic peptide research compounds studied for their complementary activity on amylin and GLP-1 receptors. This combination is commonly used in controlled laboratory research to investigate metabolic regulation, appetite signalling, glucose homeostasis, and endocrine pathways. It is of interest for studies exploring synergistic peptide interactions and energy balance mechanisms. This combination is supplied strictly for research purposes only and is not intended for human or veterinary use.
Buy 3 and save 15%
Buy 5 and save 20%
Categories
Bacteriostatic Water
AOD
Cagrilintide
Cagrilintide + Semaglutide
Retatrutide
Semaglutide
Tirzepatide
SLU PP 332
MOTS C
BPC 157
bpc-157-tb-500
Description
Overview
Biochemical Characteristics
Research Applications
Pathway / Mechanistic Context
Form & Analytical Testing
RUO Disclaimer
Overview
Biochemical Characteristics
Research Applications
Pathway / Mechanistic Context
Form & Analytical Testing
RUO Disclaimer
Overview
Cagrilintide + Semaglutide is a dual-action peptide combination combining amylin receptor agonist (cagrilintide) with GLP-1 receptor agonist (semaglutide) for synergistic metabolic effects. The combination targets multiple pathways regulating glucose homeostasis, appetite suppression, and body weight management. This peptide combination is extensively studied for its enhanced potential in supporting glucose control, body weight reduction, and metabolic health beyond monotherapy effects. Research indicates the dual agonist approach provides greater satiety signaling, improved insulin secretion, and more pronounced weight loss compared to either peptide alone. Cagrilintide + Semaglutide represents a valuable research tool for investigating combined receptor signaling, synergistic metabolic effects, and therapeutic approaches to type 2 diabetes and obesity.
Overview
Cagrilintide + Semaglutide is a dual-action peptide combination combining amylin receptor agonist (cagrilintide) with GLP-1 receptor agonist (semaglutide) for synergistic metabolic effects. The combination targets multiple pathways regulating glucose homeostasis, appetite suppression, and body weight management. This peptide combination is extensively studied for its enhanced potential in supporting glucose control, body weight reduction, and metabolic health beyond monotherapy effects. Research indicates the dual agonist approach provides greater satiety signaling, improved insulin secretion, and more pronounced weight loss compared to either peptide alone. Cagrilintide + Semaglutide represents a valuable research tool for investigating combined receptor signaling, synergistic metabolic effects, and therapeutic approaches to type 2 diabetes and obesity.
Biochemical Characteristics
Cagrilintide is a 37-amino acid amylin analog with molecular weight approximately 4,100 Da. Semaglutide is a 31-amino acid GLP-1 analog with molecular weight approximately 4,113 Da. Combined formulation enables simultaneous amylin and GLP-1 receptor activation with distinct pharmacokinetic profiles. Both peptides are water-soluble with stability across physiological pH ranges (6.5–8.0). The combination demonstrates synergistic receptor engagement and complementary metabolic effects. Cagrilintide and semaglutide show extended biological half-lives due to albumin binding modifications, supporting sustained dual signaling. Cellular uptake occurs through distinct amylin and GLP-1 receptor pathways on pancreatic, gastrointestinal, and central nervous system tissues, enabling polypharmacological metabolic regulation.
Biochemical Characteristics
Cagrilintide is a 37-amino acid amylin analog with molecular weight approximately 4,100 Da. Semaglutide is a 31-amino acid GLP-1 analog with molecular weight approximately 4,113 Da. Combined formulation enables simultaneous amylin and GLP-1 receptor activation with distinct pharmacokinetic profiles. Both peptides are water-soluble with stability across physiological pH ranges (6.5–8.0). The combination demonstrates synergistic receptor engagement and complementary metabolic effects. Cagrilintide and semaglutide show extended biological half-lives due to albumin binding modifications, supporting sustained dual signaling. Cellular uptake occurs through distinct amylin and GLP-1 receptor pathways on pancreatic, gastrointestinal, and central nervous system tissues, enabling polypharmacological metabolic regulation.
Research Applications
Glucose Homeostasis Enhancement Investigation of synergistic improvements in glucose control and insulin secretion beyond monotherapy. Body Weight Reduction Assessment of greater weight loss through combined appetite suppression and gastric slowing effects. Type 2 Diabetes Models Study of enhanced glycemic control and improved metabolic function in diabetes research. Metabolic Syndrome Investigation of improvements in multiple metabolic parameters including lipids, inflammation, and adiposity. Satiety & Appetite Control Assessment of enhanced reduction in hunger and eating behavior through dual receptor activation. Beta Cell Preservation Study of complementary protection of pancreatic beta cell function and preservation of insulin production capacity. Cardiovascular Metabolic Health Investigation of synergistic improvements in cardiometabolic risk factors and vascular function.
Research Applications
Glucose Homeostasis Enhancement Investigation of synergistic improvements in glucose control and insulin secretion beyond monotherapy. Body Weight Reduction Assessment of greater weight loss through combined appetite suppression and gastric slowing effects. Type 2 Diabetes Models Study of enhanced glycemic control and improved metabolic function in diabetes research. Metabolic Syndrome Investigation of improvements in multiple metabolic parameters including lipids, inflammation, and adiposity. Satiety & Appetite Control Assessment of enhanced reduction in hunger and eating behavior through dual receptor activation. Beta Cell Preservation Study of complementary protection of pancreatic beta cell function and preservation of insulin production capacity. Cardiovascular Metabolic Health Investigation of synergistic improvements in cardiometabolic risk factors and vascular function.
Pathway / Mechanistic Context
Amylin Receptor Activation Cagrilintide activates amylin receptors on pancreatic beta cells and gastrointestinal vagal afferents, slowing gastric emptying and promoting satiety while enhancing glucose-dependent insulin secretion. GLP-1 Receptor Signaling Semaglutide activates GLP-1 receptors on beta cells, intestinal L-cells, and hypothalamic appetite centers, enhancing insulin secretion and promoting appetite suppression and satiety. Synergistic Gastric Slowing Combined cagrilintide and semaglutide produce greater slowing of gastric emptying than either peptide alone, resulting in more pronounced nutrient absorption delays and sustained satiety. Complementary Insulin Enhancement Cagrilintide enhances glucose-dependent insulin secretion through amylin mechanisms while semaglutide promotes GLP-1-dependent insulin release, creating additive glucose control benefits. Central Appetite Suppression Both peptides cross blood-brain barrier and activate receptors in hypothalamic appetite centers, providing redundant and synergistic appetite suppression through distinct neural pathways. Beta Cell Protection Cagrilintide and semaglutide provide complementary protection of beta cell function through distinct mechanisms—amylin preservation of beta cell mass and GLP-1-dependent reduction of apoptosis.
Pathway / Mechanistic Context
Amylin Receptor Activation Cagrilintide activates amylin receptors on pancreatic beta cells and gastrointestinal vagal afferents, slowing gastric emptying and promoting satiety while enhancing glucose-dependent insulin secretion. GLP-1 Receptor Signaling Semaglutide activates GLP-1 receptors on beta cells, intestinal L-cells, and hypothalamic appetite centers, enhancing insulin secretion and promoting appetite suppression and satiety. Synergistic Gastric Slowing Combined cagrilintide and semaglutide produce greater slowing of gastric emptying than either peptide alone, resulting in more pronounced nutrient absorption delays and sustained satiety. Complementary Insulin Enhancement Cagrilintide enhances glucose-dependent insulin secretion through amylin mechanisms while semaglutide promotes GLP-1-dependent insulin release, creating additive glucose control benefits. Central Appetite Suppression Both peptides cross blood-brain barrier and activate receptors in hypothalamic appetite centers, providing redundant and synergistic appetite suppression through distinct neural pathways. Beta Cell Protection Cagrilintide and semaglutide provide complementary protection of beta cell function through distinct mechanisms—amylin preservation of beta cell mass and GLP-1-dependent reduction of apoptosis.
Preclinical Research Summary
Cagrilintide + Semaglutide is supplied as a dual-peptide formulation in sterile aqueous solution at concentrations of 1–10 mg/mL (combined peptide concentration). Storage at 2–8°C; shelf-life 12–24 months for solutions, 24–36 months for lyophilized material. Analytical testing includes HPLC separation and quantification of both cagrilintide and semaglutide with individual purity verification (≥95% each), HPLC-MS confirmation of both peptide identities, amino acid analysis of both components, and microbial sterility/endotoxin testing. Certificate of Analysis provided with each lot documenting individual peptide content and stability.
Preclinical Research Summary
Cagrilintide + Semaglutide is supplied as a dual-peptide formulation in sterile aqueous solution at concentrations of 1–10 mg/mL (combined peptide concentration). Storage at 2–8°C; shelf-life 12–24 months for solutions, 24–36 months for lyophilized material. Analytical testing includes HPLC separation and quantification of both cagrilintide and semaglutide with individual purity verification (≥95% each), HPLC-MS confirmation of both peptide identities, amino acid analysis of both components, and microbial sterility/endotoxin testing. Certificate of Analysis provided with each lot documenting individual peptide content and stability.
RUO Disclaimer
RESEARCH USE ONLY (RUO) This product is intended exclusively for laboratory research and is not approved for clinical use or human/animal administration. Not manufactured for pharmaceutical use. Users assume responsibility for suitability determination, proper storage, safety compliance, and regulatory adherence. Institutional approval (IACUC, IRB) may be required. Information provided is for research reference only and does not constitute medical advice or therapeutic claims.
RUO Disclaimer
RESEARCH USE ONLY (RUO) This product is intended exclusively for laboratory research and is not approved for clinical use or human/animal administration. Not manufactured for pharmaceutical use. Users assume responsibility for suitability determination, proper storage, safety compliance, and regulatory adherence. Institutional approval (IACUC, IRB) may be required. Information provided is for research reference only and does not constitute medical advice or therapeutic claims.
We are committed to supporting all research customers with consistent standards and professional care.
Subscribe
Subscribe to stay updated at every moment about all our news and product drops.
Terms of Service
Refund Policy
Privacy Policy
Promotional Terms
© Standard BioLabs. All rights reserved.
All products on this site are designated for Research Use Only and are supplied solely for laboratory, analytical, or scientific research purposes by qualified professionals. Products are not intended for human or animal use, and no diagnostic, therapeutic, or clinical use is intended or implied.
Standard BioLabs is a chemical supplier. Standard BioLabs is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Standard BioLabs is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.
We are committed to supporting all research customers with consistent standards and professional care.
Subscribe
Subscribe to stay updated at every moment about all our news and product drops.
Terms of Service
Refund Policy
Privacy Policy
Promotional Terms
All products on this site are designated for Research Use Only and are supplied solely for laboratory, analytical, or scientific research purposes by qualified professionals. Products are not intended for human or animal use, and no diagnostic, therapeutic, or clinical use is intended or implied.
Standard BioLabs is a chemical supplier. Standard BioLabs is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Standard BioLabs is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.
© Standard BioLabs. All rights reserved.
We are committed to supporting all research customers with consistent standards and professional care.
Subscribe
Subscribe to stay updated at every moment about all our news and product drops.
Terms of Service
Refund Policy
Privacy Policy
Promotional Terms
© Standard BioLabs. All rights reserved.
All products on this site are designated for Research Use Only and are supplied solely for laboratory, analytical, or scientific research purposes by qualified professionals. Products are not intended for human or animal use, and no diagnostic, therapeutic, or clinical use is intended or implied.
Standard BioLabs is a chemical supplier. Standard BioLabs is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Standard BioLabs is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.